Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lyell Immunopharma, Inc. LYEL
$2.52
На 18:04, 12 мая 2023
+276.98%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
612790075.00000000
-
week52high
8.74
-
week52low
1.77
-
Revenue
84683000
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-0.75000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 04:00
Описание компании
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 31 мар 2022 г. |
| Morgan Stanley | Overweight | Overweight | 06 янв 2022 г. |
| Morgan Stanley | Overweight | 12 июл 2021 г. | |
| JP Morgan | Overweight | 12 июл 2021 г. | |
| HC Wainwright & Co. | Buy | 17 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Overweight | 14 ноя 2022 г. |
| Goldman Sachs | Neutral | Buy | 11 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Seely Lynn | A | 7500000 | 7500000 | 15 дек 2022 г. |
| Thompson Rahsaan | A | 715000 | 715000 | 10 окт 2022 г. |
| Klausner Richard | D | 988900 | 11100 | 23 сент 2022 г. |
| Bishop Hans Edgar | D | 24230 | 145380 | 08 сент 2022 г. |
| Bishop Hans Edgar | A | 4685614 | 145380 | 08 сент 2022 г. |
| RIEFLIN WILLIAM JL | A | 65000 | 65000 | 08 июн 2022 г. |
| NELSEN ROBERT | A | 65000 | 65000 | 08 июн 2022 г. |
| Seely Lynn | A | 65000 | 65000 | 08 июн 2022 г. |
| NABEL ELIZABETH G | A | 65000 | 65000 | 08 июн 2022 г. |
| BRAWLEY OTIS W | A | 65000 | 65000 | 08 июн 2022 г. |
Новостная лента
Lyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
09 дек 2022 г. в 11:17
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?
Zacks Investment Research
04 ноя 2022 г. в 11:18
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewsWire
05 окт 2022 г. в 08:05
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced today that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Boston, Nov. 8 – Nov. 12, 2022. The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells. The combination of these two genetic reprogramming technologies is being incorporated in Lyell's new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy.
Wall Street Analysts Believe Lyell Immunopharma (LYEL) Could Rally 91%: Here's is How to Trade
Zacks Investment Research
12 сент 2022 г. в 11:17
The average of price targets set by Wall Street analysts indicates a potential upside of 91% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech ETF Tops in June: 5 Stocks That Outperform
Zacks Investment Research
30 июн 2022 г. в 14:52
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.